Skip to main content

cardiovascular adverse events Archives

A clue to an adverse drug event in children

May. 19, 2022—Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.

Read more


Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy

Jun. 13, 2019—More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a multi-institutional study published June 12 in the Journal of Clinical Oncology.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more